Pfizer to Buy Remaining Shares of Trillium Therapeutics
Pfizer to Buy Remaining Shares of Trillium Therapeutics
DJ Pfizer to Buy Remaining Shares of Trillium Therapeutics
DJ輝瑞將收購延齡治療公司剩餘股份
By Dave Sebastian
戴夫·塞巴斯蒂安(Dave Sebastian)
Pfizer Inc. has agreed to buy shares it didn't already own in Trillium Therapeutics Inc., a company focused on developing therapies for cancer treatment, for an implied equity value of $2.26 billion.
輝瑞公司(Pfizer Inc.)已同意以22.6億美元的隱含股權價值收購其尚未持有的Trillium治療公司(Trillium Treateutics Inc.)的股份。Trillium Treeutics Inc.是一家專注於開發癌症治療方法的公司。
The companies on Monday said Pfizer is paying $18.50 a share in cash. Trilium shares closed at $6.09 on Nasdaq on Friday.
兩家公司週一表示，輝瑞將以每股18.50美元的現金支付。Trilium股價週五在納斯達克收於6.09美元。
The deal would boost Pfizer's oncology category with the addition of immuno-therapeutics for hematological malignancies, they said.
他們説，這筆交易將增加針對血液惡性腫瘤的免疫療法，從而提升輝瑞的腫瘤學類別。
Write to Dave Sebastian at dave.sebastian@wsj.com
寫信給戴夫·塞巴斯蒂安(Dave Sebastian)，電子郵件：dave.sebastian@wsj.com
(END) Dow Jones Newswires
(完)道瓊通訊社
August 23, 2021 06:58 ET (10:58 GMT)
2021年8月23日東部時間06：58(格林尼治標準時間10：58)
Copyright (c) 2021 Dow Jones & Company, Inc.
版權所有(C)2021年道瓊斯公司